Table 3. Afatinib starting dose and adjustment with its reasons (n=133).

Afatinib treatment	Values
Starting dose, n (%)
40 mg once daily	50 (37.6)
30 mg once daily	39 (29.3)
25 mg once daily	9 (6.8)
20 mg once daily	35 (26.3)
Reasons for lower starting dose, n (%)†
Physicians’ decision based on patient’s low BMI	71 (85.5)
Financial constraint	8 (9.6)
Patient was worried about side-effects	4 (4.8)
Current treatment status, n (%)
Continued	41 (30.8)
Discontinued	92 (69.2)
Reasons for discontinuation
Disease progression	66 (49.6)
Death	4 (3.0)
Financial constraint	8 (6.0)
Side-effects	7 (5.3)
Patients’ request	5 (3.8)
Others	2 (1.5)
Dose reduction, n (%)
No	102 (76.7)
Yes	31 (23.3)
Reasons for dose reduction
Side-effects	26 (19.5)
Financial constraint	5 (3.8)

^†, number of patients =83. BMI, body mass index.